The purpose of this study is to learn about how well a vaccine (Prevnar 13, PCV13) works in preventing disease in adults with HIV. The diseases studied are pneumonia. Mostly the ones caused by the bacteria - pneumococcus. This study also evaluates the type of pneumonia that is spread into the bloodstream. All participants in the study will be identified in health care databases. Adults with HIV will be identified by looking for a medical diagnosis that has confirmed HIV from the databases. Vaccination will be identified in the databases by looking for vaccine administration or for PCV13. Participants will be followed in the databases to see if they have one of the diseases mentioned above or not. The number of vaccinated participants with the diseases will be compared to the number participants without the vaccines but with the diseases. This will help to understand how well the vaccine worked.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
PCV13 Vaccine Effectiveness (VE) for First Event of Invasive Pneumococcal Disease (IPD): Overall Follow-up
Timeframe: From index date to the earliest of death, end of health plan enrollment or end of study period (maximum up to 8.25 years)
VE for First Event of IPD at 0-3 Years of Follow-up
Timeframe: 0 to 3 years of follow up
VE for First Event of IPD at 3-5 Years of Follow-up
Timeframe: 3 to 5 years of follow up
VE for First Event of IPD at 5-7 Years of Follow-up
Timeframe: 5 to 7 years of follow up
PCV13 VE for First Event of Pneumococcal Pneumonia (PP): Overall Follow-up
Timeframe: From index date to the earliest of death, end of health plan enrollment or end of study period (maximum up to 8.25 years)
VE for First Event of PP at 0-3 Years of Follow-up
Timeframe: 0 to 3 years of follow up
VE for First Event of PP at 3-5 Years of Follow-up
Timeframe: 3 to 5 years of follow up
VE for First Event of PP at 5-7 Years of Follow-up
Timeframe: 5 to 7 years of follow up
PCV13 VE for First Event of All-cause Pneumonia (ACP): Overall Follow-up
Timeframe: From index date to the earliest of death, end of health plan enrollment or end of study period (maximum up to 8.25 years)
VE for First Event of ACP at 0-3 Years of Follow-up
Timeframe: 0 to 3 years of follow up
VE for First Event of ACP at 3-5 Years of Follow-up
Timeframe: 3 to 5 years of follow up
VE for First Event of ACP at 5-7 Years of Follow-up
Timeframe: 5 to 7 years of follow up